Article Text

Download PDFPDF
Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma

Statistics from Altmetric.com

Footnotes

  • Contributors Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript: all authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests HT: Gilead: Honoraria; Takeda: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Immunogen: Honoraria. VC: Gilead: Honoraria—Amgen: Honoraria—BMS: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. FJ: Roche: Honoraria; Janssen: Honoraria; Celgen: Honoraria.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.